KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Enterprise Value (2016 - 2025)

CRISPR Therapeutics AG's Enterprise Value history spans 11 years, with the latest figure at -$2.0 billion for Q4 2025.

  • For Q4 2025, Enterprise Value fell 3.78% year-over-year to -$2.0 billion; the TTM value through Dec 2025 reached -$2.0 billion, down 3.78%, while the annual FY2025 figure was -$2.0 billion, 3.78% down from the prior year.
  • Enterprise Value for Q4 2025 was -$2.0 billion at CRISPR Therapeutics AG, down from -$1.9 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$1.7 billion in Q4 2023 and bottomed at -$2.6 billion in Q2 2021.
  • The 5-year median for Enterprise Value is -$1.9 billion (2024), against an average of -$2.0 billion.
  • The largest annual shift saw Enterprise Value plummeted 174.0% in 2021 before it rose 23.7% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$2.4 billion in 2021, then rose by 23.7% to -$1.8 billion in 2022, then grew by 6.7% to -$1.7 billion in 2023, then dropped by 12.41% to -$1.9 billion in 2024, then decreased by 3.78% to -$2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Enterprise Value are -$2.0 billion (Q4 2025), -$1.9 billion (Q3 2025), and -$1.7 billion (Q2 2025).